Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives

Current Drug Targets

Volumn 12, Issue 3, 2011, Pages 392-419

  Hasselbalch, Hans Carl ^a   Larsen, Thomas Stauffer ^b   Riley, Caroline Hasselbalch ^a   Jensen, Morten Krogh ^a   Kiladjian, Jean Jacques ^c  

^a Roskilde Hospital ^*  (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Essential thrombocythemia; Human leukocyte IFN alpha; IFN alpha2a; IFN alpha2b; Peg IFN alpha2a; Peg IFN alpha2b; Philadelphia negative chronic myeloproliferative disorders; Polycythemia vera; Post essential thrombocythemia myelofibrosis; Post polycythemia vera myelofibrosis; Primary myelofibrosis

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHA2C INTERFERON; BUSULFAN; HYDROXYUREA; JANUS KINASE 2; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PIPOBROMAN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON; ROCERON A; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BRAIN DYSFUNCTION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOPROLIFERATIVE NEOPLASM; CLINICAL TRIAL (TOPIC); CONFUSION; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAIR LOSS; HEART DISEASE; HEMOLYTIC ANEMIA; HUMAN; KIDNEY DISEASE; LARGE CELL LYMPHOMA; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LUNG DISEASE; MALAISE; MINIMAL RESIDUAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; MYELOFIBROSIS; MYELOID METAPLASIA; NAUSEA; NEPHROTOXICITY; NEURITIS; NEUROLOGIC DISEASE; PANCYTOPENIA; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHLEBOTOMY; PNEUMONIA; POLYCYTHEMIA VERA; PREGNANCY; PROTEIN EXPRESSION; PRURITUS; PSORIASIS; QUALITY OF LIFE; RASH; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; SKIN MANIFESTATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; URTICARIA; VERTIGO;

EID: 79551631691     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011794815275     Document Type: Article

References (277)

1. Tefferi A. The Chronic Myeloproliferative Disorders. Semin Hematol 1999; 36(Supp2): 3-8.
2. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997; 11: 233-42.
3. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342(17): 1255-65.
4. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004; 41(2 Suppl 3): 1-5.
5. Fruchtman SM. Treatment paradigms in the management of chronic myeloproliferative disorders. Semin Hematol 2004; 41(2 Supp 3): 18-22.
6. Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971; 50: 357.
7. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997; 11: 233-42.
8. Hasselbalch HC. Idiopathic myelofibrosis. Am J Hematol 1990; 34: 291-300.
9. Elliot MA, Tefferi A. Thrombosis and hemorrhage in polycythemiavera and essential thrombocythemia. Br J Hematol 2005; 128: 275-90.
10. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Hematologica 2000; 85: 1126-34.
11. Thiele J, Kvasnicka HM. Prefibrotic chronic idiopathic myelofibrosis - a diagnostic enigma? Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C & Montserrat E. Acta Hematol 2004; 111: 155-9.
12. Grieshammer M, Klippel S, Strunck E, et al. PRV-1 Mrna expression discriminates two types of essential thrombocythemia. Ann Hematol 2004; 83: 364-70.
13. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at a lower risk of thrombotic complications. Blood 1999; 93: 417-24.
14. Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. In: Myelofibrosis and the Biology of Connective Tissue 1984; 427-54.
15. Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999; 78: 437-44.
16. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.
17. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005; 434: 1144-8.
18. Kralovics R, Passamonti F, Buser AS, et al. A gain-of -function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90.
19. Levine Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocytosis, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97.
20. Campbell PJ, Griesshammer M, Dohner K, et al. The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006; 107: 2098-100.
21. Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A. JAK2 (V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk Res 2006; 30: 1457-68.
22. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia:lineage specificity and clinical correlates. Br J ematol 2005; 131: 320-8.
23. Campbell PJ, Green AR. Mechanisms of disease. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-66.
24. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631-5.
25. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840-6.
26. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 2007; 21: 1952-9.
27. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B-and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Hematol 2007; 136: 745-51.
28. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia 2008; 22: 194-5.
29. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. The JAK2 V617F allelle burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis -impact on disease phenotype. Eur J Hematol 2007; 79: 508-15.
30. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110: 4030-6.
31. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden nor unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-61.
32. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomised clinical trial. Br J Hematol 2000; 110: 577-83.
33. Nielsen I, Hasselbalch HC. Acute Leukemia and myelodysplasia in patients with Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003; 74: 26-31.
34. Finazzi G, Caruso V, Marchiola R, et al. Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664-70.
35. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998; 83: 1205-13.
36. Bachleitner-Hofmann T, Gisslinger H. The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol 1999; 78(12): 533-8.
37. Gilbert HS. Modern treatment strategies in polycythemia vera. Semin Hematol 2003; 40(1 Suppl 1): 26-9.
38. Radin AI, Kim HT, Grant BW, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders. Cancer 2003; 98: 100-9.
39. Birgegaard G, Bjorkholm M, Kutti J, et al. Adverse effects and benefits of two years treatment for thrombocythemia in chronic myeloproliferative disorders. Hematologica 2004; 89: 520-7.
40. Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlogl E, Gisslinger H. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004; 101: 2239-46.
41. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108: 2037-40.
42. Steimle C, Lehmann U, Temerinac S, et al. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F. Ann Hematol 2007; 86(4): 239-44.
43. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. Complete molecular remission of polycythemia vera during long-term treatment with pegylated interferon alpha-2b. Ann Hematol 2008; 87: 847-50.
44. Kiladjian JJ, Cassinat B, Chevret S, et al. Interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-72.
45. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl -negative myeloproliferative neoplasms. Leukemia 2008; 22: 1990-8.
46. Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Leuk Res 2009; 33: 11-8.
47. Larsen TS, Møller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009; 14: 331-4.
48. Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H. Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytosis. Acta Med Austriaca 1985; 12: 123-7.
49. Velu T, Delwiche F, Gangja R, et al. Therapeutic effect of human recombinant interferon-alpha-2c in essential thrombocythemia. Oncology 1985; 42(Suppl 1): 10-4.
50. Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 1983; 99:789-92.
51. Ludwig H, Linkesch W, Gisslinger H, et al. Interferon alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunotherapy 1987; 25:266-73.
52. Gugliotta L, Macchi S, Catani L. Recombinant alpha-2 interferon (alpha-IFN) in the treatment of essential thrombocythemia. Preliminary report. Hematologica 1987;72:277-9.
53. Giles FJ, Gray AG, Brozovic M, et al. Alpha-interferon therapy for essential thrombocythemia. Lancet 1988; 2: 70-2.
54. Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythemia by alpha-2a interferon. Lancet 1988; 332: 960-7
55. Silver RT. Recombinant interferon-alpha for the treatment of polycythemia vera. Lancet 1988; 2: 403.
56. May D, Wandl UB, Niederle N. Treatment of essential thrombocythemia with interferon-alpha-2b. Lancet 1989; 1: 96.
57. Gisslinger H, Linkesch W, Fritz E, Ludwig H, Chott A, Radaskiewicz TH. Long term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1989; 1: 634-7.
58. Lazzarino M, Vitale A, Morra E, et al. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. Br J Hematol 1989; 72: 173-7.
59. Tichelli A. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2c. Blut 1989; 58: 15-19.
60. Talpaz M, Kurzrock R, Kantarjian H, O'Brien S, Gutterman JU. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 1989; 86: 554-558.60.
61. Silver RT. A new treatment for polycythemia vera: recombinant interferon alpha. Blood 1990; 76: 664-5.
62. Silver RT. Interferon in the treatment of the myeloproliferative disorders. Semin Hematol 1990; 27: 6.
63. Lazzarino M, Vitale, Morra E, et al. Therapy of essential thrombocythemia with alpha-interferon: results and prospects. Eur J Hematol 1990; 45: 15-21.
64. Ariad S, Bezwoda WR. Alpha-interferon for polycythemia vera. Blood 1991; 77: 670.
65. Cacciola E, Giustolisi R, Guglielmo P, Di Raimondo F, Cacciola E, Calogero RD. Recombinant interferon alpha in the treatment of polycythemia vera. Blood 1991; 77: 2790-6.
66. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H. Interferon in essential thrombocythemia. Br J Hematol 1991; 79(Suppl 1): 42-7.
67. Yataganas X, Meletis J, Plata E, et al. Alpha interferon treatment of essential thrombocythemia and other myeloproliferative disorders with excessive thrombocytosis. Eur J Cancer 1991; 27(Suppl 4): S69-S71.
68. Silver R. Response: recombinant interferon-alpha in the treatment of polycythemia vera. Blood 1991; 12: 2790-91.
69. Giles F. Maintenance therapy in myeloproliferative disorders: the current options. Br J Hematol 1991; 79(Suppl 1): 92-5.
70. Turri D, Mitra ME, Di Trapani R, Lipari MG, Perricone R, Cajozzo A. Alpha-interferon in polycythemia vera and essential thrombocythemia. Hematologica 1991; 76: 75-7.
71. De Wolf JTM, Hendriks DW, Egger RC, Esselink MT, Halie MR, Vellenga E. Alpha-interferon for intractable pruritus in polycythemia vera. Lancet 1991; 337: 241.
72. Sacchi S, Tabilio A, Leoni P, et al. Interferon alpha-2b in the longterm treatment of essential thrombocythemia. Ann Hematol 1991; 63: 206-9.
73. Seewann HL, Zikulnig R, Gallhofer G, Schmid C. Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon-alpha-2b. Eur J Cancer 1991; 27: S58-63.
74. Legrand C, Belluci S, Disdier M, Edelman L, Tobelem G. Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia. Am J Hematol 1991; 38: 307.
75. Middelhoff G, Boll I. A long-term clinical trial of interferon alphatherapy in essential thrombocythemia. Ann Hematol 1992; 64: 207-9.
76. Teofili IL, De Stefano V, Iovino MS, et al. Disappearance of spontaneous erythroid colonies in patients with myeloproliferative disorders treated by alpha-interferon. Br J Hematol 1992; 81: 310-1.
77. Kasparau H, Bernhard M, Krieger O, Lutz D. Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia. Eur J Hematol 1992; 48: 33-6.
78. Lopes E, Ribeiro MM, Silva MJ, Gandra M, Principe F, Granato C. Essential thrombocythemia: clinical features, therapy and followup of 12 cases. Leukemia 1992; 6(Suppl 3): 138S-40S.
79. Sacchi S, Tabilio A, Leoni P, et al. Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term aIFN treatment. Ann Hematol 1993; 66: 245-6.
80. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alpha. Am J Hemol 1993; 43: 316-8.
81. Silver RT. Interferon-alpha2b: a new treatment for polycythemia vera. Ann Int Med 1993; 119: 1091-2.
82. Cimino R, Rametta V, Matera C, Mele G, Mettivier V, Ferra F. Recombinant interferon alpha-2b in the treatment of polycythemia vera. Am J Hematol 1993; 44: 155-7.
83. Hino M, Futami E, Okuno S, Miki T, Nishizawa Y, Morii H. Possible selective effect of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 1993; 66: 161-2.
84. Van Genderen PJ, Michiels JJ. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann Hematol 1993; 2: 57-62.
85. Sacchi S, Leono P, Liberati M, et al. A prospective comparison between treatment with phlebotomy alone and interferon-alpha in patients with polycythemia vera. Ann Hematol 1994; 68: 247-50.
86. Rametta V, Ferrara F, Marottoli V, Matera C, Mettivier V, Cimino R. Recombinant interferon alpha2b as treatment of essential thrombocythemia. Acta Hematol 1994; 91: 126-9.
87. Messora C, Bensi L, Vecchi A, et al. Cytogenetic conversion in a case of polycythemia vera treated with interferon-alpha. Br J Hematol 1994; 86: 402-4.
88. Papineschi F, Bucallossi A, Capochiani E, et al. Recombinant alpha2a interferon and polycythemia vera: clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. Eur J Hematol 1994; 53: 213-7.
89. Brand CM, Leadhester L, Budiman R, Lechner K, Gisslinger H. Succesful re-treatment of an anti-interferon resistant polycythemia vera patient with lymphoblastoid interferon -alphaN1 and in vitro studies on the specificity of the antibodies. Br J Hematol 1994; 86: 216-8.
90. Merup M, Tornebohm-Roche E, Engman K, Paul C. Human leucocyte interferon-alpha therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-alpha2a. Eur J Cancer 1994; 30A: 1729-30.
91. Tornebohm-Roche E, Merup M, Lockner D, Paul C. Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. Am J Hematol 1994; 48: 163-7.
92. Muller W, de Wolf JT, Egger R, et al. Long-term treatment with interferon -a2b for severe pruritus in patients with polycythemia vera. Br J Hematol 1995; 89: 313-8.
93. Foa P, Massaro P, Ribera S, et al. Role of interferon alpha-2a in the treatment of polycythemia vera. Am J Hematol 1995; 48: 55-7.
94. Sacchi S. The role of alpha-interferon in essential thrombocythemia, polycythemia vera, and myelofibrosis with myeloid metaplasia. Leuk Lymphoma 1995; 19: 13-20.
95. Parmeggianni L, Ferrant A, Rodhain J, Michaux JL, Sokal G. Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur J Hematol 1987; 39: 228-32.
96. Wickramasinghe SN, Stanley P, Gill DS. Alpha-interferon in primary myelofibrosis. Lancet 1987; 330: 1524-25.
97. Hilali AM, Haque SK, Al-Freih N. A case of acute (malignant) myelofibrosis responding promptly to alpha-2 interferon treatment. Blood 1987; (Suppl 1): 70,239.
98. Bevan PC, Bateman CJT. Interferon alpha for idiopathic myelofibrosis. Lancet 1988; i: 766.
99. Barosi G, Libertato LN, Costa A, Ascari E. Cytoreductive effects of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 1989; 58: 271-4.
100. Barosi G, Liberato LN, Costa A, et al. Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. Eur J Hematol 1990; 45(Suppl 52): 12-14.
101. List AF, Kummet TD, Kerr DM. Acute myelofibrosis: response to recombinant human interferon alpha-2a. Leuk Res 1990; 14: 321-6.
102. Martyre MC, Magdelenat H, Calvo F. Interferon-gamma in vivo reverses the increased platelet levels of platelet derived growth factor and transforming growth factor B in patients with myelofibrosis with myeloid metaplasia. Br J Hematol 1991; 77: 431-5.
103. Craig JIO, Anthony RS, Parker AC. Circulating progenitor cells in myelofibrosis: the effect of recombinant alpha2b interferon in vivo and in vitro. Br J Hematol 1991; 78: 155-60.
104. Radin AI, Buckley P, Duffy TP. Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia. Hematol Pathol 1991; 5: 83-8.
105. Seewann HL, Gastl G, Lang A, et al. Interferon-alpha2 in the treatment of idiopathic myelofibrosis. Blut 1988; 56: 161-3.
106. Gastl G, Lang A, Huber CH, Seewan H. Interferon-alpha for idiopathic myelofibrosis. Lancet 1988; i: 765-6.
107. Hasselbalch H. Interferon in myelofibrosis. Lancet 1988; i: 355.
108. Turri D, Mitra ME, Di Trapani R, Caiozzo A. Alpha interferon in primary myelofibrosis. Hematologica 1989; 74: 417-8.
109. McCarthy D, Clark J, Giles F. The treatment of myelofibrosis with alfa-interferon. Br J Hematol 1991; 78: 590-1.
110. List AF, Doll DC. Alpha-interferon in the treatment of idiopathic myelofibrosis. Br J Hematol 1992; 80: 566-7.
111. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996; 22(Suppl 1): 135-42.
112. Reilly JT, Vellenga E, De Wolff THM. Interferon treatment in polycythemia vera. Leuk Lymphoma 1996; 22 (Suppl 1): 143-8.
113. Taylor PC, Dolan G, Ng J-P, Paul B, Collin R, Reilly J. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythemia vera: a study of 17 patients and an analysis of published data. Br J Hematol 1996; 92: 55-9.
114. Berte R, Vallisa D, Ferrai B, Civardi G, Sbolli G, Cavanna L. Lowdose interferon alpha treatment in essential thrombocythemia. Eur J Hematol 1996; 56: 104-5.
115. Clemons MJ, Williams YF, Goldman JM, Barrett AJ. Long-term control of polycythemia vera with recombinant alpha interferon. Hematol Oncol 1996; 14: 37-40.
116. Silver R. Interferon alpha: effects of long-term treatment for polycythemia vera. Semin Hematol 1997; 34: 40-50.
117. Stasi R, Brunetti M, Bussa S, et al. Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythemia vera. J Intern Med 1997; 242: 143-7.
118. Gisslinger H, Musil N, Rintelen C, Sillaber C, Gisslinger B, Lechner K. Recombinant interferon-alpha in the treatment of polycythemia vera. Blood 1997; Abstract 4065.
119. Hansmann E, Bremer K, Busche G, Kappel I, Georgii A. Interferon-alpha therapy in polycythemia vera. Blood 1997; Abstract 4066.
120. Massaro P, Foa P, Pomati M, et al. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol 1997; 56: 126-8.
121. Tefferi A, Elliot MA, Solberg LH Jr., Silverstein MN. New drugs in essential thrombocythemia and polycythemia vera. Blood 1997; 11: 1-7.
122. Stasi R, Brunetti M, Bussa S, et al. Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythemia vera. J Intern Med 1997; 242: 143-7.
123. Stasi R, Venditti A, Del Poeta G, et al. Role of human leucocyte interferon (alpha) in the treatment of patients with polycythemia vera. Am J Med Sci 1998; 315: 237-41.
124. Domingues MA, Haepers AT, Massaut IH, Vassalo J, Lorand-Metze I. Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with alpha-interferon. Hematologica 1998; 83: 1124-5.
125. Foa P, Massaro P, Caldiera S, LaTargia ML, et al. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythemia vera. Eur J Hematol 1998; 60: 273-7.
126. Sacchi S, Gugliotta L, Papineschi F, et al. Alpha-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia 1998; 12: 289-94.
127. Ozturk A, Gunay A, Uskent N. Therapeutic efficacy of recombinant interferon-alpha in polycythemia vera. Acta Hematologica 1998; 99: 89-91.
128. Heis N, Rintelen C, Gisslinger B, Knobl P, Lechner K, Gisslinger H. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Hematol 1999; 62: 27-31.
129. Bentley M, Taylor K, Griggs A, et al. Long term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia. Leuk Lymphoma 1999; 36: 123-8.
130. Lengfelder E, Berger U, Hehlmann R. Interferon-alpha in the treatment of polycythemia vera. Ann Hematol 2000; 79:103-9.
131. Merup M, Aberg W, Lowenberg E, et al. Symptoms, symptom distress and health related quality of life in patients with polycythemia vera or essential thrombocythemia during treatment with interferon-alpha. Acta Oncol 2002; 41: 50-5.
132. Alvarado Y, Cortes I, Verstovsek S, et al. Pilot study of pegylated interferon alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 2003; 51: 81-6.
133. Fruehauf S, Topaly J, Villalobos M, Veldwijk MR, Laufs S, Ho AD. Quantitative real-time polymerase chain reaction shows that treatment with interferon reduces the initially upregulated PRV-1 expression in polycythemia vera patients. Hematologica 2003; 88: 349-51.
134. Verstovsek S, Lawhorn K, Giles F, et al. Peg-Intron for myeloproliferative diseases: an update of ongoing Phase II study (abstract). Blood 2004; 104: 424a.
135. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Hematologica 2005; 90:1333-8.
136. Saba R, Jabbour E, Giles F, et al. Interferon-alpha therapy for patients with essential thrombocythemia. Cancer 2005; 103: 2551-7.
137. Gugliotta L, Bulgarelli S, Vianelli N, et al. PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET). Final Report of a Phase II Study. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 2600.
138. Gugliotta L, Bulgarelli S, Asioli S, et al. Bone marrow evaluation according to the PVSG and WHO criteria in 90 essential thrombocythemia (ET) patients treated with PEG interferon alpha-2b. Preliminary results. Blood 2005; 106: 316 (abstract 4962).
139. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2005; 107: 3339-41.
140. Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Sem Thromb Hemostas 2006; 32: 409-14.
141. Samuelsson J, Hasselbalch H, Bruserod O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia. Feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006; 106: 2397-405.
142. Samuelsson J, Mutschler M, Birgegard G, Gram-Hansen P, Bjorkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Hematologica 2006; 91: 1281-2.
143. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006; 107: 451-8.
144. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders. Final results of a phase 2 study. Cancer 2007; 110: 2012-6.
145. Tutaeva VV, Misurin AV, Michiels JJ, et al. Application of PRV-1 mRNA expression level and JAK2V617F mutation for differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. Hematology 2007; 12: 473-9.
146. Ishii T, Xu M, Zhao Y, Hu W-Y, Ciurea S, Bruno E, Hoffman R. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera. Hematologica 2007; 21: 373-4.
147. Levy B, Vandris K, Adriano F, Goldman J, Silver RT. Recombinant interferon alpha (rIFN) may retard progression of early primary myelofibrosis by reducing splenomegaly and by changing marrow morphology. Blood 2008; 112: Abstract 1758. ASH Annual Meeting Abstracts.
148. Kiladjian JJ, Dupont S, Cassinat B, et al. Can Peg-(IFN)-2a eradicate JAK2V617F-positive bone marrow progenitors in polycythemia vera (PV). Blood 2008; 112: abstract 659.
149. Quintas-Cardama A, Kantarjian HM, et al. Pegylated interferonalfa-2a therapy yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009 27: 5418-24.
150. Silver RT, Vandris K. Recombinant interferon alpha(rIFN-alpha-2b) may retard progression of early myelofibrosis. Leukemia 2009; 23: 1366-9.
151. Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-IFN-2a therapy in patients with myelofibrosis. A study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Hematol 2009; 146: 218-30.
152. Buxhofer-Ausch V, Gisslinger H, Berg T, Gisslinger B, Kralovics R. Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. Eur J Hematol 2009; 82: 161-3.
153. Heron I, Hokland M, Berh K. Enhanced expression of beta2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 1978; 75: 6215-9.
154. van't Hull E, Schellekens H, Lowenberg B, de Vrie MJ. Influence of interferon preparations on the proliferative capacity of human and mouse bone marrow cells in vitro. Cancer Res 1978; 38: 911.
155. Dukes PP, Izadi P, Ortega JA, Shora NA, Gomperts E. Inhibitory effects of interferon on mouse megakaryocytic progenitor cells in culture. Exp Hematol 1980; 8: 1048.
156. Lotzova E, Savary CA, Gutterman JU, Hersch EM. Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-alpha. Cancer Res 1982; 42: 2480-8.
157. Neumann HA, Fauser AA. Effect of interferon on pluripotent hematopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 1982; 10: 587-90.
158. Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotent (CFU-GEMM), erytrhoid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983; 131: 1300-5.
159. Lin S, Kikuchi T, Pledger W, Tamm I. Interferon inhibits the establishment of competence in GO/S phase transition. Science 1986; 233: 356-9.
160. Ganser A, Carlo-Stella C, Greher J, Volkers B, Holzer D. Effect of interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987; 70: 1173-9.
161. Nissen MH, Larsen JK, Plesner T, Olesen BK, Ernst P. Alphainterferon induces enhanced expression of HLA-ABC antigens and beta2-microglobulin in vivo and in vitro in various subsets of human lymphoid cells. Clin Exp Immunol 1987; 69: 632-8.
162. Foa R, Fierro MT, Lusso P, et al. The effect of alpha-interferon on the immune system of patients with hairy cell leukemia. Leukemia 1987; 1: 377.
163. Carlo Stella C, Cazolla M, Ganser A, et al. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 1987; 70: 1014-9.
164. Carlo Stella C, Cazzola M. Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. Hematologica 1988; 73: 225.
165. Gugliotta L, Bagnara GP, Catani L, Gaggiol L, Guarni A, Zauli G. In vivo and in vitro inhibitory effect of interferon on megakaryocyte colony growth in essential thrombocythemia. Br J Hematol 1989; 71: 177-81.
166. Chott A, Gisslinger H, Thiele J, et al. Interferon-alpha-induced morphological changes of megakaryocytes: A histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Hematol 1990; 74: 10-6.
167. Sinzinger H, Linkesch W, Ludwig H, et al. Impaired conversion of exogenous arachidonic and by platelets to thromboxane b2 and correction of that deficiency by interferon-alpha. Prostaglandins 1990; 40: 351-60.
168. Muller CA, Walz J, Zinser R, Buhring HJ, Steinke B, Schmidt H. In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN-alfa treatment. Ann Hematol 1991; 63: 259-63.
169. Wadenvik H, Kutti J, Ridelli B, et al. The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 1991; 77: 2103-8.
170. Franco V, Florena AM, Aragona F, Campesi G. Morphometric study of the bone marrow in polycythemia vera following interferon therapy. Pathol Res Pract 1993; 189: 52-7.
171. Castello G, Lerza R, Cerruti A, et al. The in vitro effect of recombinant interferon-alpha-2a on circulating hematopoietic progenitors in polycythemia vera. Br J Hematol 1994; 87: 621-3.
172. Peschel C, Aulitzky WE, Huber C. Influence of interferon -alpha on cytokine expression by bone marrow microenvironment -impact on treatment of myeloproliferative disorders. Leukemia Lymphoma 1996; 22(Suppl 1): 129-34.
173. Grander D, Sangfelt O, Erickson S. How does interferon exert its cell growth inhibitory effect? Eur J Hematol 1997; 59: 129-35.
174. Wang O, Miyakawa Y, Fox N, et al. Interferon-alfa directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 2093-107.
175. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leucocyte Biol 2002; 71: 565-81.
176. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
177. Krause CD, Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 2005; 106: 299-346.
178. Platanias LC. Mechanisms of type 1-and type II-interferonmediated signalling. Nat Rev Immunol 2005; 5: 375-86.
179. Billiau A. Interferon: The pathways of discovery 1. Molecular and cellular aspects. Cytokine Growth Factor Rev 2006; 17: 381-409.
180. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007; 282: 20047-51.
181. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007; 282: 20053-7.
182. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89: 884-93.
183. Bracci L, Proietti E, Belardelli F. IFN-alpha and novel strategies of combination therapy for cancer. Ann N Y Acad Sci 2007; 1112: 256-68.
184. Gamero AM, Young HA, Wiltrout RH. Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 2004; 5: 111-2.
185. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54.
186. Lesinski GB, Anghelina M, Zimmerer J, et al. The antitumor effects of IFN-a are abrogated in A STAT1-deficient mouse. J Clin Invest 2003; 112: 170-80.
187. Yu H, Jove R. The STATs of cancer. New molecular targets come of age. Nat Rev 2004; 4: 97-105.
188. Bromberg J, Darnell JE, Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19: 2468-73.
189. Burdelya L, Kujawski M, Niu G, et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxidemediated antitumor effects. J Immunol 2005; 174: 3925-31.
190. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005; 65: 939-47.
191. Wang W, Edington HD, Rao Uma MN, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNA2b. Clin Cancer Res 2007; 13: 1523-317.
192. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-18.
193. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon a-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24: 3164-71.
194. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. a-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64: 5934-7.
195. Okada H, Tsugawa T, Sato H, et al. Delivery of interferon-a transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res 2004; 64: 5830-8.
196. Tosi D, Valenti R, Cova A, et al. Role of cross-talk between IFN-ainduced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol 2004; 172: 5363-70.
197. Abele R, Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 2004; 19: 216-24.
198. Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol 2004; 228: 130-7.
199. Cresswell AC, Sisley K, Laws D, Parsons MA, Rennie IG, Murray AK. Reduced expression of TAP-1 and TAP-2 in posterior uveal melanoma is associated with progression to metastatic disease. Melanoma Res 2001; 11: 275-81.
200. Whiteside TL, Stanson J, Shurin MR, Ferrone S. Antigenprocessing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 2004; 173: 1526-34.
201. Yanai Y, Sanou O. Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions. J Interferon Cytokine Res 2001; 21: 835-41.
202. Hibbert L, Foster GR. Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J Interferon Cytokine Res 1999; 19: 309-18.
203. Ortaldo JR, Herberman RB. A species of human alpha interferon that lacks the ability to boost human natural killer activity. Proc Natl Acad Sci USA 1984; 81: 4926-9.
204. Greiner JW, Fischer PB. Differential effects of recombinant human leucocyte interferons on cell surface antigen expression. Cancer Res 1986; 46: 4984-90.
205. Hilkens CMU, Schhlaak JF. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol 2003; 171: 5255-63.
206. Kawade Y, Watanabe Y. Neutralization of interferon by antibody: appraisals of methods of determining and expressing the neutralizing titre. J Interferon Res 1984; 4: 571-84.
207. Steis RG, Smith JW, Urba WJ, et al.Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988; 318: 1409.
208. Catani L, Gugliotta L, Zauli G, et al. In vitro inhibition of interferon alpha-2a antiproliferative activity by antibodies developed during treatment for essential thrombocythemia. Hematologica 1989; 77: 318-21.
209. Oberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alpha-2b: development of neutralising interferon antibodies and possible loss of antitumor activity. Natl Cancer Inst USA 1989; 81: 531-5.
210. von Bussow P, Jakschies D, Freund M, et al. Treatment of antirecombinant interferon-alpha 2 antibody positive patients with natural interferon-alpha. Br J Hematol 1991; 78: 210-6.
211. von Bussow P, Pralle H, Hochkeppel H, et al. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia. Blood 1991; 78: 38-43.
212. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralising antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882-5.
213. Prummer O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter study. Cancer 1993; 71: 1828-34.
214. Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006; 108: 3223-4.
215. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-8.
216. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-34.
217. Remacha AF, Estivill C, Sarda MP, et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Hematologica 2007; 92: 285-6.
218. Pardanani A, Lasho TL, Schwager S, et al. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia 2007; 21: 1828-9.
219. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 2008; 111: 4922-9.
220. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in postpolycythemia vera myelofibrosis. Blood 2008; 111: 3383-7.
221. Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia:prognostic factors for thrombosis, bleeding, myelofibrosis and leukaemia. Arch Intern Med 2005; 165: 2651-8.
222. Alvarez-Larran A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218-23.
223. Gangat N, Wolanskyj AP, McClure RF, Schwager S, Tefferi A. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270-6.
224. Tefferi A, Gangat N, Wolanskyj AP, et al. 20+ years without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Hematol 2008; 80: 386-90.
225. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 2001; 80: 160-5.
226. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma 2006; 47: 381-96.
227. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: inter-observer reliablity and utility for identifying disease subtypes. Blood 2008; 111: 60-70.
228. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279-84.
229. Hsiao HH, Yang MY, Liu YC, et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 2007; 35: 1704-7.
230. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109: 2310-3.
231. Tefferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007; 21: 2074-5.
232. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001; 15: 419-29.
233. Bukowski RM, Tandler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmokinetic profile and dosing guidelines for an improved interferon - alpha-2b formulation. Cancer 2002; 95: 389-96.
234. Hasselbalch HC. A possible role for interferon in the treatment of idiopathic myelofibrosis. Med Hypothesis 1988; 27: 345-6.
235. Barosi G, Bordessoule D, Briere J, et al. European Myelofibrosis Network. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005; 106: 2849-53.
236. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401-7.
237. Steegmann JL, Requena MJ, Martin-Regueira P, et al. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha. Am J Hematol 2003; 72: 170-6.
238. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007; 282: 20047-51.
239. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006; 32(4 Part 2): 417-21.
240. Kiladjian JJ, Chevret S, Dosquet C, Fenaux P, Chomienne C, Rain JD. Long-Term Outcome in Polycythemia Vera (PV): final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi). Blood 2008; 112: Abstract 1746.
241. McMullin MF, Bareford D, Campbell P, et al. General Hematology Task Force of the British Committee for Standards in Hematology. Guidelines for the diagnosis, investigation and management of polycythemia/erythrocytosis. Br J Hematol 2005; 130: 174-95.
242. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Hematol 2005; 129: 293-306.
243. Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Hematologica 2005; 90: 1477-83.
244. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost 2006; 32(4 Pt 2): 422-9.
245. Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. The management and outcome of four pregnancies in women with idiopathic myelofibrosis Br J Hematol 2008; 142: 480-2.
246. Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev 2008; 22: 235-45.
247. Seror J, Sentilhes L, Lefebvre-Lacoeuille C, Marpeau L. Interferonalpha for treatment of essential thrombocythemia during pregnancy: case report and review of the literature. Fetal Diagn Ther 2009; 25: 136-40.
248. Vantroyen B, Vantraelen D. Management of essential throbocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment: a comparative analysis of the literature. Acta Hematol 2002; 107: 158-69.
249. Martinelli P, Martinelli V, Agangi A, et al. Interferon alpha treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gynecol 2004; 191: 2016-20.
250. Ozaslan E, Yilmaz R, Simsek H, Tatar G. Interferon therapy for acute hepatitis C during pregnancy. Ann Pharmacother 2002; 36: 1715-8.
251. Pons JC, Lebon P, Frydman R, Delfraissy JF. Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 1995; 10: 7-10.
252. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Hematologica 2004; 89: 215-32.
253. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 617F mutation. Blood 2007; 110: 485-89.
254. Griesshammer M, Grunewald M, Michiels JJ. Acquired thrombophilia in pregnancy: essential thrombocythemia. Semin Thromb Hemost 2003; 29: 205-12.
255. Washita T, Fujitani M, Yamamoto Y, Katsurada T, Yoshida Y. Interferon-alfa treatment of essential thrombocythemia during pregnancy. Intern Med 2006; 45: 1161-4.
256. Milano V, Gabrielli S, Rizzo N, et al. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. J Matern Fetal Med 1996; 5: 74-8.
257. Iki S, Usuki K, Kotaki M, Yamaguchi Y. Successful pregnancy and delivery during alpha-interferon therapy for essential thrombocythemia (in Japanese). Rinsho Ketsueki 1999; 40: 1201-3.
258. Delage R, Demers C, Cantin G, Roy J. Treatment of essential thrombocythemia during pregnancy with interferon-alpha. Obstet Gynecol 1996; 87: 814-7.
259. Williams JM, Schlesinger PE, Gray AG. Successful treatment of essential thrombocythemia and recurrent abortion with alphainterferon. Br J Hematol 1994; 88: 647-8.
260. Petit JJ, Callis M, Fernandez de Sevilla A. Normal pregnancy in a patient with essential thrombocythemia treated with interferon alpha-2b. Am J Hematol 1992; 40: 80.
261. Pardini S, Dore F, Murineddu M, et al. Alpha 2b interferon therapy and pregnancy: report of a case of essential thrombocythemia. Am J Hematol 1993; 43: 78-9.
262. Diez-Martin JL, Banas MH, Fernandez MN. Childbearing age patients with essential thrombocythemia: should they be placed on interferon? Am J Hematol 1996; 52: 331-2.
263. Pérez-Encinas M, Bello JL, Pérez-Crespo S, De Miguel R, Tome S. Familial myeloproliferative syndrome. Am J Hematol 1994; 46: 225-9.
264. Pulik M, Lionnet F, Genet P, Petitdidier C, Jary L. Platelet counts during pregnancy in essential thrombocythemia treated with recombinant alpha-interferon. Br J Hematol 1996; 93: 495.
265. Shilberg O, Shimon I, Sofer O, Dolitski M, Ben-Bassat I. Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythemia. Br J Hematol 1996; 92: 491-3.
266. Vianelli N, Gugliotta L, Tura S, Bovicelli L, Rizzo N, Gabrielli A. Interferon-alpha 2a treatment in a pregnant woman with essential thrombocythemia. Blood 1994; 83: 874-5.
267. Thornley S, Manoharan A. Successful treatment of essential thrombocythemia with alpha interferon during pregnancy. Eur J Hematol 1994; 52: 63-4.
268. Koh LP, Devendra K, Tien SL. Four pregnancies in two patients with essential thrombocythemia: a case report. Ann Acad Med Singapore 2002; 31: 353-6.
269. Hasselbalch HC, Clausen NT, Jensen BA. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. Am J Hematol 2002; 70: 92-9.
270. Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Hematologica 2008; 93: 1260-1.
271. Girodon F, Schaeffer C, Cleyrat C, et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617Fpositive patients within the first years of hydroxyurea therapy. Hematologica 2008; 93: 1723-7.
272. Theocharides A, Passweg JR, Medinger M, et al. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Hematologica 2008; 93: 1890-3.
273. Spanoudakis E, Bazdiara I, Kotsianidis I, et al. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. Ann Hematol 2009; 88: 629-32.
274. Larsen TS, Stricker K, Pallisgaard N, Moeller MB, Hasselbalch HC. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology 2009; 14: 11-5.
275. Carlo-Stella C, Cazzola M, Ganser A, et al. Effects of recombinant and gamma interferons on the in vitro growth of circulating hematopoietic stem cells (CFU-GEMM, CFU-MK, BFU-C, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 1987; 70: 1014-9.
276. Essers MAG, Offner S, Blanco-Bose WE, et al. IFNa activates dormant hematopoietic stem cells in vivo. Nature 2009; 458: 904-8.
277. Trumpp A, Essers M, Wilson A. Awakening dormant hematopoietic stem cells. Nat Rev Immunol 2010; 10: 201-9.